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ABSTRACT
Introduction: In the 20 years since its introduction to the palette of intravenous hemodynamic 
therapies, the inodilator levosimendan has established itself as a valuable asset for the management 
of acute decompensated heart failure. Its pharmacology is notable for delivering inotropy via calcium 
sensitization without an increase in myocardial oxygen consumption.
Areas covered: Experience with levosimendan has led to its applications expanding into perioperative 
hemodynamic support and various critical care settings, as well as an array of situations associated with 
acutely decompensated heart failure, such as right ventricular failure, cardiogenic shock with multi- 
organ dysfunction, and cardio-renal syndrome. Evidence suggests that levosimendan may be preferable 
to milrinone for patients in cardiogenic shock after cardiac surgery or for weaning from extracorporeal 
life support and may be superior to dobutamine in terms of short-term survival, especially in patients 
on beta-blockers. Positive effects on kidney function have been noted, further differentiating levosi-
mendan from catecholamines and phosphodiesterase inhibitors.
Expert opinion:Levosimendan can be a valuable resource in the treatment of acute cardiac dysfunc-
tion, especially in the presence of beta-blockers or ischemic cardiomyopathy. When attention is given to 
avoiding or correcting hypovolemia and hypokalemia, an early use of the drug in the treatment 
algorithm is preferred.
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1. Introduction
Inotropic therapy has a long-established, although not always 
clearly defined, place in the treatment of heart failure. In the 
case of acute heart failure (AHF), whether arising de novo as 
a consequence of a myocardial infarction or as 
a decompensation of chronic congestive HF, intravenous (i.v.) 
adrenergic agents have been used for decades and may be 
regarded as the benchmark for agents of this sort. Experience 
with these agents has been problematic, however, with exten-
sive reports of adverse events such as the development of 
cardiac arrhythmias and renal dysfunction [1] and little, if any, 
reliable indication that these interventions are associated with 
improved survival. In fact, substantial evidence points toward 
an increase in mortality when dobutamine is used in AHF [2] 
or when epinephrine is used in patients with cardiogenic 
shock (CS) [3]. Even norepinephrine, which is currently pre-
ferred to epinephrine in CS or AHF, was not associated with 
a survival benefit in a large collection of data [4,5].
Other inotropic agents, such as the phosphodiesterase 
(PDE)-III inhibitors milrinone and enoximone, have proved to 
be less than fully satisfactory alternatives to dobutamine [6–8], 
probably because these two drug families share a common 
denominator, namely that their inotropic action derives from 
calcium mobilization and hence an increase in myocardial 
oxygen consumption.
In a separate line of research started in the early 1990s, 
agents were discovered which enhance cardiac contractility by 
making cardiac muscle fibers more sensitive to free ionic 
calcium, instead of relying on increased concentrations of 
intracellular calcium.
Levosimendan is a product of that research – indeed it 
might be described as the product of that research, since no 
comparable or similar agent has yet matured into an interna-
tionally approved therapeutic with a recognized role in the 
treatment of AHF, despite several decades of effort and inves-
tigation [9]. Since 2000, when i.v. levosimendan (SIMDAX®) 
was first approved for clinical administration it has become 
an established part of the inotropic repertoire for AHF. Its 
pharmacology has been extensively documented, and it has 
been evaluated in a wide range of other acute situations 
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characterized by cardiac dysfunction, congestion, and hypo-
perfusion. In this concise review, we examine the evidence for 
the use of levosimendan in these various settings and offer 
some practical guidance on its safe and effective use.
2. Overview of levosimendan pharmacology
The emergence of levosimendan is grounded in research into 
the molecular structure and functions of the cardiac isoform of 
troponin C (TnC) [9,10]. The inotropic action of levosimendan 
derives from its selective binding to TnC [11–13], via which it 
promotes inotropy without increasing myocardial oxygen con-
sumption [14–16]. This is potentially an important considera-
tion for patients, many of whom may be in a state of 
precarious myocardial energy balance, and it provides a clear 
mechanistic differentiation from conventional inotropes, 
which rely on mobilizing ionic calcium, often at some expense 
to the cellular energy balance.
The other principal pharmacological effect of levosimendan 
is the mediation of vascular dilatation via the opening of 
adenosine triphosphate-sensitive potassium (KATP) channels 
in vascular smooth muscle cells [17], which causes reductions 
in preload and afterload and a reduction of vascular resistance 
in key organs [18,19]. Levosimendan can thus be defined as an 
inodilator. Of note in this context is a recent paper by Longrois 
and colleagues that highlighted the advantages of inodilators 
over inotropes when a less cardiocentric and more integrated 
framework is considered for the treatment of AHF [20].
As a third mechanism of action, levosimendan has been 
shown to open the mitochondrial KATP channels in several 
organs, including the heart, leading to ischemia-protective 
effects [17,21,22] as well as to pre- and post-conditioning 
cardioprotection [23–26], and to anti-remodeling [27]. 
Additional pharmacological actions of levosimendan have 
been reported, including activation of nitric oxide synthase 
[28], inhibition of oxidative stress and apoptosis, and 
modulation of autophagy [22,25,29–31]. The properties of 
levosimendan as a modulator of the oxidant/antioxidant bal-
ance and its protective effects on mitochondrial function have 
also been explored in CS/low cardiac output syndrome (LCOS) 
patients [32]. It has been suggested that these various ancil-
lary actions of levosimendan may be relevant to its clinical 
profile in various scenarios [17] (Figure 1).
An active metabolite designated OR-1896 with close clinical 
functional similarities to its parent drug, as both an inotrope 
and a vasodilator, has been characterized in detail [34,35]. The 
persistence of this metabolite in the body (for up to a week 
after an infusion of the parent drug) underwrites the extended 
duration of effect of levosimendan and has been exploited in 
clinical practice, especially for the management of advanced 
HF in ambulatory, non-hospitalized patients.
As a summary, the principal hemodynamic effects of both 
levosimendan and its metabolite are dose-dependent 
enhancement of cardiac inotropy and CO and reductions in 
both right atrial pressure and pulmonary capillary wedge 
pressure (PCWP) [36]. Systemic vascular resistance is also 
reduced [37] as is pulmonary vascular resistance (PVR), notably 
in patients with right HF or pulmonary hypertension [38]. 
These qualities identify the potential of levosimendan in 
cases of acutely decompensated HF characterized by low CO 
and impaired organ perfusion as an intervention that (1) 
improves hemodynamics and tissue perfusion, (2) relieves 
symptoms of congestion and fatigue, and (3) normalizes neu-
rohormone levels.
Levosimendan has been shown to exert selective vasodila-
tor effects in the renal vasculature that augment renal blood 
flow (RBF) and glomerular filtration rate (GFR) and increase 
urine production [39–41]. These nominally renal-protective 
actions may also be relevant in the management of AHF, 
particularly in cases of cardio-renal syndrome, where dysfunc-
tion of either organ may induce dysfunction of the other. For 
completeness, we note that preliminary data have been 
obtained about effects of levosimendan on the liver 
[25,42,43] which warrant further exploration in this direction.
3. Levosimendan in acute cardiac care
3.1. Acutely decompensated HF
Levosimendan was pioneered as a treatment for acutely 
decompensated heart failure/acute heart failure (AHF) and 
its efficacy and safety in that indication have been demon-
strated in randomized controlled trials involving >6000 
patients, supplemented by real-world experience. 
Comparison with other drugs in this indication shows super-
iority in hemodynamic, neurohormonal, and symptomatic 
effects, with no signals of an adverse impact on longer-term 
survival [44]. Findings from meta-analysis aggregating data 
from >6000 patients, plus a real-world registry involving 
>5000 patients, are indicative of at least relative long-term 
survival benefit from levosimendan. At a minimum – and in 
clear contrast to the use of adrenergic/calcium-mobilizing 
inotropes such as dobutamine and epinephrine – use of 
levosimendan does not appear to be associated with 
increased mortality [4,45], with overall figures showing 
Article highlights
● The inodilator levosimendan is established in the repertoire of hemo-
dynamic therapies for severe heart failure with various etiologies, and 
in various clinical settings.
● The unique mechanism of action and pharmacology of levosimendan 
make it a safe choice for restoring hemodynamic and neurohormonal 
balance, alleviating symptoms and protecting cardiac tissue.
● In acute cardiac care, the evidence-base for using levosimendan in 
patients with acutely decompensated chronic heart failure treated 
with beta-blockers is much stronger than for any other inotrope or 
inodilator.
● Levosimendan evokes specific vasodilation of the renal afferent 
(preglomerular) arterioles, allowing the restoration of renal function 
and reducing the need for renal replacement therapy after cardiac 
surgery.
● The efficacy of levosimendan has been investigated but is still to be 
definitely proven in other clinical settings, such as right heart failure, 
perioperative low cardiac output syndrome, cardiogenic and septic 
shock, etc. To date, non-regulatory studies have mostly been per-
formed in these areas; properly powered randomized controlled trials 
are warranted.
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a strong trend – albeit not a significant one – toward an 
increase in survival (Figure 2). This may be regarded as con-
firming the proposition that inotropy via calcium sensitization 
is preferable to that achieved via calcium mobilization, which 
is associated with enhanced myocardial oxygen consumption, 
increased heart rate, and greater risk of arrhythmias, which 
may contribute to worse morbidity and mortality out-
comes [46].
Of further note is that the non-adrenergic mechanism of 
action of levosimendan means that it retains pharmacological 
and clinical effectiveness in patients pretreated with beta-
blockers [49]. This quality has assumed prominence in an era 
when beta-blockers are widely used in the management of HF 
and the extant European Society of Cardiology (ESC) guide-
lines expressly identify the use of levosimendan as an option 
to ‘reverse the effect of beta-blockade if beta-blockade is 
thought to be contributing to hypotension with subsequent 
hypoperfusion’ [50]. Conceptually, this advantageous feature 
of bypassing unavailable beta-1-adrenergic receptors could be 
extrapolated to the common problem of downregulation 
(desensitization) of beta-1-adrenergic receptors faced in the 
context of AHF or sepsis, especially after prolonged exposure 
to dobutamine [51,52].
More generally, the ESC guidelines frame the i.v. use of 
levosimendan and other classes of inotropes, including 
adrenergic agents such as dobutamine and the PDE inhi-
bitors, with the advice that their short-term use ‘may be 
considered in patients with hypotension (SBP <90 mmHg) 
and/or signs/symptoms of hypoperfusion despite adequate 
filling status, to increase cardiac output, increase blood 
pressure, improve peripheral perfusion and maintain end- 
organ function’ [50].
Levosimendan remains the only drug of its kind to have 
firmly established itself in the clinical repertoire of treat-
ments for AHF [53] and its profile as an inotrope that 
provides short-term clinical benefits without adverse long- 
term outcomes has been nominated as a benchmark for 
future developments [54]. Encouraging reports of the 
impact of levosimendan on the quality of life of AHF 
patients are relevant in this context [55].
HF patients who might derive particular benefit from levo-
simendan therapy include: (a) those with HF of ischemic ori-
gins; (b) those with well-sustained systemic blood pressure 
Figure 1. An overview of the pleiotropic actions of levosimendan. Levosimendan acts as an inotrope by enhancing the calcium sensitivity of troponin C in heart 
muscle, thereby increasing the force of contraction and ensuring an enhancement of cardiac output, without a commensurate increase in the oxygen requirements 
of the heart. A similar action may occur in the slow skeletal muscle fibers, for instance in the diaphragm, that would be of help in weaning from ventilation or in 
delaying the need for ventilation in patients with amyotrophic lateral sclerosis. By opening adenosine triphosphate-sensitive potassium channels in the vascular 
smooth muscle cells of certain vessels, levosimendan causes vasodilation and a reduction in systemic vascular resistance (SVR), which is also seen as a decrease in 
pulmonary capillary wedge pressure (PCWP), and ensuring an enhancement of cardiac output, in addition to its inotropic actions. A similar action on mitochondrial 
and sarcolemmal KATP channels in cardiac myocytes is linked to cardioprotection. Finally, the preferential vasodilation achieved by levosimendan on afferent versus 
efferent glomerular arterioles increases the glomerular filtration rate (GFR) without increasing renal oxygen demand. (From Kurdi et al. [33] with permission.).
Figure 2. Meta-analysis of the effect of levosimendan on 31-day survival in the 
four phase III regulatory trials submitted to the authorities for the introduction 
of levosimendan as a treatment for acutely decompensated heart failure: LIDO 
(203 patients) [47]; RUSSLAN (504 patients) [48]; REVIVE 1 and 2 (700 patients) 
[107]; and SURVIVE (1327 patients) [117]. Pooled statistics were calculated using 
the Cochran–Mantel–Haenszel test, controlling for study. Total events in the 
pooled levosimendan arms were 167/1519 (11.0%) and total events in the 
pooled comparator arms were 145/1215 (11.9%). Odds ratio 0.81; 95% confi-
dence interval 0.64–1.04.
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(systolic blood pressure [SBP] >100 mmHg); and (c) those 
being treated with beta-blockers.
Since its first introduction as a treatment for AHF in 2000, 
levosimendan has also been used to provide hemodynamic 
support in perioperative and critical care settings, CS, various 
forms of weaning (including from inotropic support), and 
advanced HF [56]. Additional applications identified for further 
appraisal have been identified and will be examined in this 
commentary [57].
3.2. Perioperative hemodynamic support
Pre- or peri-operative reduced left ventricular function is 
a prominent risk factor for LCOS in patients undergoing car-
diac surgery, so there is a rationale to investigate the use of 
levosimendan to avert the emergence of LCOS. Peri-operative 
use of levosimendan was not associated with a statistically 
significant impact on overall mortality in three recent trials 
[58], but a trajectory toward survival benefit was noted in the 
LEVO-CTS trial, which also produced suggestions of greater 
clinical benefit in patients with severely reduced (<35%) pre-
operative left ventricular ejection fraction (LVEF), especially in 
isolated coronary artery bypass grafting (CABG) [59]. A lower 
overall incidence of acute kidney injury (p= 0.02) was also 
recorded, as well as less need for renal replacement therapy 
(p= 0.02).
In a single-center study, pre-treatment with levosimendan 
in patients undergoing surgical myocardial revascularization 
resulted in less myocardial injury, a reduction in tracheal 
intubation time, less requirement for inotropic support, and 
a shorter length of intensive care unit (ICU) stay [60]. Patients 
receiving a short infusion of levosimendan before CABG 
showed evidence of less myocardial damage, suggestive of 
a preconditioning effect [61] and emphasizing the importance 
of administering levosimendan as early as possible before 
surgery.
Several of these findings have been corroborated in 
a meta-analysis [62] that also identified a reduced risk of post- 
operative LCOS and reduced mechanical support require-
ments in patients with pre-operative LVEF <35% (p = 0.05). 
In a recent meta-analysis by Weber et al. [63] involving 27 
randomized controlled trials and 3198 patients, a significant 
reduction in mortality was shown for prophylactic use of 
levosimendan in patients with severely impaired LVEF under-
going cardiac surgery (odds ratio [OR] 0.67; 95% confidence 
interval [CI] 0.49–0.91; p= 0.0087). Furthermore, the inci-
dences of LCOS (OR 0.56, 95% CI 0.42–0.75; p< 0.0001), 
acute kidney injury (OR 0.63; 95% CI 0.46–0.86; p= 0.0039) 
and renal replacement therapy (OR 0.70; 95% CI 0.50–0.98; 
p= 0.0332) were also significantly decreased in the levosimen-
dan group, suggesting beneficial effects from the prophylac-
tic use of levosimendan in patients with severely impaired 
LVEF undergoing cardiac surgery. No comparable data are 
available for any other inotropes, several of which have 
been associated with detrimental effects on outcome [8,58].
Expert commentary on this use of levosimendan empha-
sizes the need for adequate hemodynamic monitoring to 
anticipate, prevent or treat vasodilatation-related side effects 
and recommends avoidance of bolus dosing outside the oper-
ating room [64].
3.3. Right ventricular failure and pulmonary 
hypertension
Right heart dysfunction and failure are frequent complications 
in patients undergoing cardiac surgery; they are associated 
with increased mortality and may be aggravated by post-
operative pulmonary hypertension after weaning from cardio-
pulmonary bypass [65,66]. In addition to measures to reduce 
right ventricular (RV) afterload by administration of inhaled 
vasodilators and improving systemic perfusion pressure (and, 
thereby, RV coronary blood flow), augmentation of LV function 
with inotropic support is one key element in the medical 
response and levosimendan, which augments myocardial con-
tractility and reduces PVR, is well configured for this applica-
tion [67]. In addition, it is known that alterations in cellular 
calcium handling and contractile proteins may contribute to 
changes in RV inotropic response. Muscle elongation may 
result in mechanisms that may not support sarcoplasmic reti-
culum calcium uptake, and a decreased RV homeometric auto-
regulation is associated with alterations in calcium 
homeostasis in muscle strips isolated from terminally failing 
human hearts [68]. Because of its mechanism of action, levo-
simendan increases RV stroke work without affecting RV myo-
cardial oxygen consumption, leading to an improvement in RV 
myocardial external efficiency in RV dysfunction [69].
A meta-analysis [70] of responses to levosimendan in 
patients suffering from acute right HF has identified 
a reduction in PVR and an increase in RVEF. These findings 
are complemented by the demonstration that levosimendan 
exerts multiple nominally beneficial hemodynamic and organ- 
protective effects in experimental pulmonary hypertension/RV 
failure [71].
First results of the phase II regulatory randomized con-
trolled trial HELP (Hemodynamic Evaluation of Levosimendan 
in Patients With PH-HFpEF) [72] were disclosed at the 2020 
Heart Failure Society of America Annual Scientific Meeting 
[73]. The primary efficacy endpoint of this 37-patient study 
(PCWP during exercise) did not demonstrate a statistically sig-
nificant reduction from baseline. However, levosimendan sig-
nificantly reduced PCWP compared with baseline (p≤ 0.0017) 
and placebo (p≤ 0.0475) when the measurements at rest, with 
legs elevated and on exercise were combined. Levosimendan 
was also associated with a statistically significant improvement 
in 6-minute walk distance compared with placebo 
(p= 0.0329) [74].
3.4. Septic shock
Theoretical considerations, experimental research and data 
from small clinical trials support the expectation of 
a beneficial impact of levosimendan in septic shock [75]. 
Against these must be set the findings of the LeoPARDS trial 
[76], which recorded no clear benefit for prevention of organ 
dysfunction, albeit that levosimendan infusion was broadly 
very well tolerated. Reasons have been adduced to explain 
the negative outcome of the LeoPARDS trial, such as the 
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liberal inclusion criteria, specifically moderate circulatory fail-
ure or the lack of septic cardiomyopathy (SCM) per se to justify 
the use of an inodilating drug in an already hypotensive 
patient [77], which leaves open the need for further investiga-
tion more specific to sepsis-induced HF.
The currently available clinical evidence in septic shock 
indicates that: (a) levosimendan may be a viable alternative 
to dobutamine in severe de novo AHF associated with SCM 
and may offer additional extra-cardiac effects arising from 
amelioration of multi-organ failure (MOF); and (b) indiscrimi-
nate use of levosimendan (i.e. in patients with hypotension 
but without evidence of myocardial dysfunction) to prevent 
the development of MOF is hemodynamically safe but may 
not deliver clinical benefits. Further insights – if not the defi-
nitive answer – may emerge from the observational study 
GLASSES 1 (Levosimendan and Global Longitudinal Strain 
Assessment in Sepsis), the protocol of which was published 
very recently [78].
Further research in SCM is needed to examine possible 
interplay between the severity of cardiac failure and the tim-
ing of treatment. More generally, the risks associated with the 
use of vasoactive catecholamines make levosimendan 
a potentially useful substitute in a dobutamine-sparing 
approach for patients requiring inotropes. Lacking a fully evi-
denced alternative, however, recent guidelines [79,80] still 
recommend dobutamine as the first-line inotrope in cases of 
septic shock, despite various considerations and observations 
that indicate it may be associated with worse outcomes.
We remind readers that an inodilator should never be used 
as a first-line drug in septic shock, as reducing SVR further will 
worsen the hemodynamic imbalance. However, in cases of 
severe myocardial depression, an inodilator such as levosi-
mendan has a role in augmenting CO. In such cases we 
recommend use in conjunction with a vasopressor.
3.5. Cardiogenic shock
Acute myocardial infarction (AMI) is the most common etiol-
ogy of CS but CS may arise from any situation of acute, severe 
dysfunction in either ventricle of the heart. CS, which most 
usually (but not invariably) arises as a complication of AMI, is 
associated with very high mortality [81].
The current standard of care for CS includes primary percu-
taneous coronary intervention (for the initiating AMI), fluid 
therapy, vasopressors, inotropes and – in cases of persistent 
shock and in selected patients – the use of mechanical circu-
latory support [82–84].
Various small studies have produced indications that levo-
simendan may be a valid alternative to conventional inotropes 
for the management of CS. For instance, levosimendan (24 µg/ 
kg bolus, then 0.1 µg/kg/min for 24 h) was superior to dobu-
tamine (initial dose 5 µg/kg/min, with subsequent dose 
increases to reach the desired hemodynamic effect) for enhan-
cing cardiac power output, even though both drugs evoked 
similar reductions in PCWP in a trial of 22 consecutive AMI 
patients who developed CS [85].
In an exploratory randomized controlled study in CS sec-
ondary to AMI (n= 32), levosimendan compared favorably with 
the PDE inhibitor enoximone [86]. Levosimendan (12 µg/kg 
over 10 min, followed by 0.1 µg/kg/min over 50 min, then 
0.2 µg/kg/min for the next 23 h) or enoximone (fractional 
loading dose of 0.5 mg/kg, then 2–10 µg/kg/min continuously) 
were administered as add-on therapies to a regimen of revas-
cularization, intra-aortic balloon pump counterpulsation, and 
conventional inotropes.
Beneficial hemodynamic effects were recorded in both 
groups but were achieved sooner with levosimendan. In addi-
tion, there were no deaths from MOF in the levosimendan 
group, compared with four in the enoximone group, and there 
was a significant 30-day survival advantage with levosimendan 
(69% vs 37%; p= 0.023).
A recent meta-analysis [87] of data from 13 studies 
(n= 648) about the effect of levosimendan in CS complicating 
AMI concluded that levosimendan use improved hemody-
namic parameters and cardiac function and that there was 
no indication of an adverse effect on mortality. A separate 
similar analysis performed under the auspices of the 
Cochrane Database of Systematic Reviews [88] (13 studies; 
n= 2001) concluded that, at present, there is no definitive 
evidence favoring any inotrope or vasodilator over any 
others with regard to reduction of mortality in hemodynami-
cally unstable patients with CS. The sole exception to this 
conclusion was an indication of a short-term survival benefit 
from levosimendan when compared with dobutamine. 
However, the level of evidence underpinning that finding 
was considered inconclusive and in need of fuller evaluation 
in adequately designed and powered prospective controlled 
trials.
Pending the completion of such trials, the use of levosi-
mendan may be considered in cases of low CO associated with 
signs of hypoperfusion or deteriorating renal/liver function, 
especially if beta-blocker use is part of the clinical scenario. It 
may also be considered as a salvage therapy after dobutamine 
failure.
3.6. Weaning from respiratory and circulatory support
A substantial proportion of intubated patients in ICUs are 
difficult to wean from mechanical ventilation, with impacts 
on morbidity and mortality. Factors thought to contribute to 
this phenomenon include pulmonary congestion owing to HF 
and the development of diaphragm weakness. The pathophy-
siology of diaphragm weakness includes altered calcium sen-
sitivity of the contractile proteins, so it is plausible that 
levosimendan may improve prospects for successful weaning 
in some patients [89].
In a prospective observational study in ventilator- 
dependent difficult-to-wean ICU patients with diminished 
LVEF (<40%), levosimendan improved cardiac contractility 
and oxygenation variables and increased the likelihood of 
successful separation from mechanical ventilatory support 
[90]. In a recently reported, double-blind, randomized, pla-
cebo-controlled trial (NCT01721434) in patients weaning 
from mechanical ventilation via continuous positive airways 
pressure, levosimendan increased minute ventilation but no 
direct effect on diaphragm contractile efficiency was identi-
fied [91].
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In other research, two retrospective studies of weaning 
from venoarterial extracorporeal membrane oxygenation (VA- 
ECMO) [92,93] concluded that use of levosimendan was asso-
ciated with a substantial improvement in weaning success 
rates and with lower 30-day mortality (p= 0.016) and better 
long-term survival [93]. Very recent data [94] show that levo-
simendan enables weaning from extracorporeal life support 
without increasing norepinephrine requirements when com-
pared with a control group receiving milrinone. There are also 
indications that levosimendan may offer further potential ben-
efits in this situation, including improvements in ventriculo- 
arterial coupling and endothelial function [90,94].
As a side note, recent data were collected on the role of 
levosimendan in weaning children requiring VA-ECMO after 
cardiac surgery [95]. In an observational study, 118 eligible 
children received 145 ECMO runs and, in 55 cases, levosimen-
dan was administered before decannulation. In the controlled 
analysis, levosimendan was associated with decreased risks of 
both weaning failure (adjusted relative risk 0.20; 95% CI 0.07–-
0.57) and in-hospital mortality (adjusted relative risk 0.45; 95% 
CI 0.26–0.76).
3.7. Takotsubo syndrome
Levosimendan has also been considered for inotropic support 
in Takotsubo syndrome when extracorporeal life support is 
unavailable [96]. Takotsubo syndrome-induced HF and CS are 
commonly treated with aggressive diuresis, hemodynamic 
support, and inotropic drugs. The fact that catecholamines 
are implicated in the pathogenesis of Takotsubo syndrome 
suggests that levosimendan may be considered as a viable 
option for inotropic therapy [97]. Supportive clinical data have 
been presented by Santoro et al. [98] and Yaman et al. [99]. In 
a very recent review [100], Santoro and colleagues go one step 
further toward characterizing the use of levosimendan in this 
therapeutic setting by stating that it may represent an option 
for Takotsubo patients, but that its use should be limited to 
patients with impaired systolic function, without left outflow 
tract obstruction and with systolic arterial pressure ≥90 mm 
Hg. We agree with Tavazzi et al. [101] that, despite a lack of 
data on the best treatment strategy for the acute Takotsubo 
phase, some reports have demonstrated a positive effect of 
levosimendan in accelerating ventricular function recovery.
4. Renal function effects
There are indications that in patients with HF and associated 
impaired renal function levosimendan may exert renal- 
protective effects via both an increase in CO – hence with 
a proportional increase in RBF – and a specific renal vasodila-
tory influence evidenced as a net afferent (preglomerular) 
vasodilatation of renal arterioles, which augments GFR [102]. 
Of further note, the increase in GFR is matched by an increase 
in renal oxygen delivery, thus mitigating the risk of under- 
oxygenation of the renal medulla, which is vulnerable to 
ischemia.
Pertinently, detailed clinical research has both clarified the 
effects of levosimendan on the glomerular vasculature and 
demonstrated that levosimendan-induced augmentation of 
GFR does not compromise renal oxygenation [41], thus differ-
entiating levosimendan in functionally important ways from 
agents such as dobutamine and milrinone [103,104] (Figure 3).
In a recent frequentist network meta-analysis [105] levosi-
mendan appeared as a safe renal-protective choice for the 
treatment of patients undergoing cardiac surgery, especially 
for those with low systolic function, decreasing the risk of 
mortality and acute renal injury.
These observations notwithstanding, evidence for 
a substantive clinical impact on renal function in HF is still to 
be confirmed by further randomized controlled trials. Some 
light, however, was recently shed by Guerrero-Orriach and 
colleagues [106], who reported the results of the FIM-BGC 
-2014-01 (Renal and Neurologic Benefit of Levosimendan vs 
Dobutamine in Patients With Low Cardiac Output Syndrome 
After Cardiac Surgery) clinical trial, in which levosimendan 
showed a beneficial effect on renal function in LCOS patients 
after cardiac surgery that was independent from CO and 
vascular tone.
5. Safety and tolerability data
In the REVIVE-II study, 52.6% of levosimendan-treated patients 
experienced a reduction in BP, compared with 37.9% in the 
placebo group (p< 0.001) [107]
The primary endpoint of REVIVE was a composite outcome 
measuring changes in clinical status during the first 5 days 
after randomization. Judged by that metric, patients rando-
mized to levosimendan were less likely to deteriorate than 
those in the control group (p= 0.015), even though intensifica-
tion of adjunctive therapy occurred more frequently in pla-
cebo-treated patients. Conversely, levosimendan was 
Figure 3. Relative (%) changes in glomerular filtration rate (GFR), renal blood 
flow (RBF), and cardiac index (CI), after administration of levosimendan (gray) 
versus dobutamine (white) in the randomized trial (32 patients) reported by 
Lannemyr et al. [103]. Following treatment, the levosimendan and dobutamine 
groups displayed similar increases in CI and RBF with no significant differences 
between groups. In contrast, GFR increased by 22% in the levosimendan group 
but remained unchanged in the dobutamine group (p= 0.012). Filtration frac-
tion was not affected by levosimendan but decreased by 17% with dobutamine 
(p= 0.045).
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associated with more frequent hypotension and cardiac 
arrhythmias during the infusion period and with 
a numerically greater risk of death (p= 0.29).
Retrospective analyses of the data from that trial identified 
an association between low baseline arterial BP (BABP; speci-
fied as SBP <100 mmHg or diastolic BP [DBP] <60 mmHg) and 
increased mortality risk in patients treated with levosimendan: 
mortality was 27% for levosimendan versus 16% in the pla-
cebo group. (This excess mortality was incurred entirely during 
the index admission [15 vs six deaths]; deaths during follow- 
up were identical in the two groups [n= 29]). Exclusion of 
patients with low BABP eliminated this early excess mortality: 
overall mortality in patients with well-supported BP at baseline 
was then similar (levosimendan, n= 15 [7.9%]; placebo, n= 18 
[9.1%]; hazard ratio 0.92; p= 0.81). The study’s composite 
primary endpoint was still positive for levosimendan in the 
subset of patients with higher BABP.
These findings identified low BABP as a possible risk 
factor for the use of levosimendan and the current sum-
mary of product characteristics advises that levosimendan 
should be used with caution – and with no bolus dose – in 
patients with presenting SBP <100 mmHg and/or DBP 
<60 mmHg, or those with actual pressures above those 
thresholds but who are deemed to be at risk of developing 
hypotension. The 2016 ESC HF guidelines [50] consider 
that these exclusion criteria are likely to apply only to 
a small proportion of the eligible AHF population. 
Hypovolemia should be corrected as a precautionary mea-
sure, prior to infusion.
An integrated safety data summary from the pivotal 
placebo-controlled studies of i.v. levosimendan in AHF 
(prepared by Orion Pharma, which discovered and devel-
oped levosimendan and sponsored the studies in question) 
revealed no difference in the proportions of patients 
experiencing a reduction in arterial BP in response to 
levosimendan infusion (23.1% in both groups).
The integrated safety summary also identified a greater 
likelihood of atrial arrhythmias with levosimendan than pla-
cebo (8.2% vs 5.4%; p= 0.024). This difference was slightly 
more marked than the average in the REVIVE-II study (9% vs 
2%; p< 0.001). A statistically significant difference in the inci-
dences of ventricular tachycardia was also noted in REVIVE-II 
(levosimendan, 25%; placebo, 17%; p= 0.031) but that differ-
ence was not replicated in the integrated data (levosimendan, 
10.0%; placebo, 11.3%; p= 0.371). There were no statistically 
significant differences between the levosimendan and placebo 
groups in respect of cardiac ischemia (7.3% vs 8.9%, p= 0.233), 
reduction in hemoglobin (2.3% vs 3.8%, p= 0.058), hypokale-
mia (4.9% vs 7.0%, p= 0.059), or increase in blood glucose 
(1.6% vs 2.6%, p= 0.117).
The incidences of worsening HF and renal function distur-
bances, recorded as adverse events, were significantly lower in 
the levosimendan group than the placebo group (HF events, 
15.6% vs 28.4%; p< 0.001; renal events, 6.9% vs 10.4%, 
p= 0.007). These data are compatible with the potential renal- 
protective effect of levosimendan addressed earlier in this 
commentary but are not proof of such an effect.
The safety profile of levosimendan in AHF has also been the 
subject of a meta-analysis by Gong and colleagues [108] (25 
randomized trials, 5349 patients). That analysis indicated 
increased risks of recurrence of extrasystoles (relative risk 
[RR] 1.88; 95% CI 1.26–2.81; p= 0.002), headache or migraine 
(RR 1.94; 95% CI 1.54–2.43; p< 0.00001), and hypotension (RR 
1.33; 95% CI 1.15–1.53; p= 0.0001) in patients with HF when 
levosimendan was compared with combined control therapy 
of placebo or dobutamine. A separate meta-analysis by 
Landoni et al. [109] (45 trials, 5480 patients) failed to show 
any statistically significant increased risks of MI (25 studies; RR 
0.786; 95% CI 0.522–1.185; p= 0.3), ventricular arrhythmias 
(nine studies; RR 0.855; 95% CI 0.611–1.281; p= 0.5), supraven-
tricular arrhythmias (19 studies; RR 1.005; 95% CI 0.782–1.291; 
p= 0.9), hypotension (22 studies; RR 1.389; 95% CI 0.996–1.936; 
p= 0.053), or the composite endpoint of hypotension and/or 
norepinephrine use (25 studies; RR 1.219; 95% CI 0.954–1.558; 
p= 0.11).
6. Use and posology
As a general principle, the use of inotropes – when judged 
appropriate – should be restricted to the lowest dose and the 
shortest possible period [110]. Within that general framework, 
our collective opinion, based on many years of first-hand 
experience with levosimendan in clinical settings, is that it 
should, as a rule, be administered without a loading bolus 
(to mitigate any risk of hypotension). Exceptions to this gui-
dance may arise in cases of cardiac surgery patients present-
ing with severe myocardial dysfunction, so as to ensure the 
administration of an adequate dose before aortic cross- 
clamping.
Currently accepted good practice is to initiate a continuous 
infusion (for up to 24 h) at infusion rates of 0.05–0.1 μg/kg/ 
min. Alternatively, therapy may be commenced at a dose of 
0.2 μg/kg/min for the first 60 min (to attain the desired 
therapeutic effect more rapidly) before reducing it to 0.1 μg/ 
kg/min. In either event, the infusion rate should be closely 
monitored and individualized according to tolerability and 
hemodynamic response. CO monitoring is highly desirable in 
order to titrate dosage according to response. After levosi-
mendan is introduced in CS, dobutamine may be weaned 
depending on the hemodynamic and clinical responses. 
Established chronic HF treatments should be (re-)introduced 
promptly after weaning of vasopressors.
Levosimendan can exert profound vasodilatory effects and 
so should be administered with caution in patients with low 
BP. Hypovolemia should be excluded using echocardiography 
and/or advanced monitoring and evaluation of dynamic 
indices before and during levosimendan treatment; observa-
tion of that precaution may extend to dose adjustment for any 
i.v. diuretics that are being used. Serum potassium levels 
should be maintained at ≥4.0 mmol/L during infusion, to 
prevent the emergence of hypokalemia [111].
We agree with the recently published opinion [112] that 
‘the nearly total absence of evidence of benefit with some of 
the traditional IV drugs used in acute heart failure [. . .] (such as 
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the catecholamines or the PDE inhibitors) would warrant their 
elimination from routine use in favor of treatments where 
such evidence has been accrued (e.g. for levosimendan).’ We 
concur likewise with the verdict that ‘ . . . an earlier use of 
levosimendan in the therapy of acute heart failure has been 
shown to be of benefit’ [113,114].
7. Expert opinion
Levosimendan has established itself as a valuable resource in 
the management of acute decompensated HF and is one of 
very few successful medical innovations of its kind introduced 
in that field in recent decades. Its pharmacology is notable for 
delivering inotropy without an increase in myocardial oxygen 
consumption and for an array of secondary effects that include 
pre-conditioning and post-conditioning, as well as anti- 
ischemic, cardioprotective, and anti-oxidative effects. 
Proceeding from those properties, it has been proposed that, 
in addition to its use in various scenarios of low CO, levosi-
mendan may be beneficial in other conditions associated with 
acutely decompensated HF, including RV failure, peri- 
operative hemodynamic support to prevent LCOS, and cardio-
genic and septic shock. The potential of levosimendan to 
protect the kidneys in situations of cardio-renal syndrome 
has been identified. In addition, current lines of investigation 
include the administration of levosimendan as repeated inter-
mittent infusions to sustain patients with advanced HF, and its 
application in a range of critical care settings, including 
Takotsubo syndrome [115].
The evolution of levosimendan has not, however, been 
uniformly unproblematic with non-attainment of primary end-
points in several large, controlled trials, including REVIVE II, 
LICORN, Levo-CTS and LEOPARDS. Particularly in REVIVE II the 
hazards of hypotension in the context of levosimendan use 
were clearly apparent and are acknowledged in the extant 
prescribing information and recommended posology. In the 
case of trials in cardiac surgery patients with or at risk of LCOS 
or in sepsis patients, plausible explanations have been put 
forward to explain the lack of success, but those must never-
theless be recognized as post hoc rationalizations for neutral 
or inconclusive outcomes and new investigations are 
warranted.
It has also to be recognized that the role and value of 
levosimendan in pulmonary hypertension is slender and 
inconclusive and that detailed discrimination between pul-
monary hypertension in the context of right ventricular failure 
as opposed to pulmonary hypertension in the context of lung 
disease will be needed.
These qualifying remarks themselves must be put in 
context: a recent update of an online-assisted consensus 
process identified levosimendan as one of 10 non-surgical 
interventions that significantly reduce mortality in cardiac 
surgery and a majority opinion (55% of contributors) recom-
mended its use in low ejection fraction (<35%) patients 
undergoing CABG to reduce mortality (Grade 1B) [116]. 
This is a useful illustration of the importance of careful 
subgroup analysis in reconceptualizing a drug with an intri-
cate pharmacology to address specific, sometimes niche, 
treatment requirements for complex clinical scenarios. The 
impact of levosimendan on the risk of acute kidney injury 
(prespecified in these studies as a secondary endpoint) is 
another important finding that should not be obscured by 
the inconclusive primary endpoint results of those studies 
but which will require further clinical investigations to 
define the optimal deployment of levosimendan for this 
purpose.
Overarching these specific considerations is the fact that 
when compared with conventional adrenergic, calcium- 
mobilizing inotropes, levosimendan has been shown in multi-
ple assessments to be associated with lower mortality. The 
deleterious effects of adrenergic inotropes are now too clearly 
apparent to be easily overlooked and in our opinion the fact 
that levosimendan can often substitute for those agents with 
no loss of effectiveness and no adverse impact on survival is 
sufficient reason to favor its use in many situations. The pro-
minent absence of any signal for increased mortality with 
levosimendan in the ALARM-HF registry [4] suggests to us 
that levosimendan is the inotrope least likely to worsen prog-
nosis. Given the scale of the mortality effect recorded with 
other agents in the ALARM-HF dataset this is a substantial 
consideration in its own right. More than a decade ago the 
SURVIVE trial investigators [117] noted that in AHF ‘there is 
a need for agents that at least improve hemodynamics and 
relieve symptoms without adversely affecting survival’. In the 
intervening years, levosimendan has reliably met that stan-
dard for AHF and offers a similar advantageous profile for 
the other clinical scenarios examined in this review.
As a final recommendation regarding posology, we remind 
the reader that in the treatment algorithm of acute cardiac 
dysfunction, early use of levosimendan has been shown to be 
of benefit especially in the presence of beta-blockers, provided 
that hypovolemia and hypokalemia are averted.
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